

Addressing Lung Cancer Biomarker Testing Through Project ECHO

Post Session 2: Recap & Resources

This document compiles some of the key resources mentioned during the **Session 2: Adequate Tissue for Sampling**. To review all publications, articles, or commentaries mentioned, we recommend reviewing the presentation recording and PowerPoint presentation.

All slides and recordings can be found [here](#).

SESSION FEEDBACK

Post Session Feedback Forum [Link](#)

Feel free to provide additional feedback on Session 2 as well as the future sessions. All responses will be confidential.

HIGHLIGHTS OF SESSION RESOURCES

Obtaining Specimen for Sampling

- Adequacy of Samples by EBUS-TBNA for Molecular Analysis Systematic Review & Meta-Analysis [Link](#)
- Feasibility of EBUS-TBNA for NGS [Link](#)
- Feasibility of EBUS-TBNA for massively parallel NGS in thoracic cancer patients [Link](#)
- FNA smears as a potential source of DNA for targeted NGS of lung adenocarcinomas [Link](#)

Testing & Treatment for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

- A targeted NGS method- identifying clinically relevant mutation profiles in lung adenocarcinoma [Link](#)
- Amivantamab in EGFR Exon 20 Insertion: Initial Results (CHRYSALIS Phase I Study) [Link](#)
- Comparison of four chemotherapy regimens (2002) [Link](#)
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma [Link](#)
- Phase III study comparing cisplatin plus gemcitabine with cisplatin plus (2008) [Link](#)
- Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer (ADAURA Trial) [Link](#)

Practice guidelines:

- Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced NSCLC [Link](#)
- Genomic Profiling of Advanced NSCLC in Community Settings: Gaps and Opportunities [Link](#)
- IASLC Global Molecular Database for Thoracic Malignancies [Link](#)
- Methods for staging NSCLC: Diagnosis and management of lung cancer [Link](#)
- Molecular testing guidelines for treatment with targeted Tyrosine Kinase Inhibitors [Link](#)
- NCCN Clinical Practice Guidelines® NSCLC Version 9-2022 [Link](#)

TOOLS/RESOURCE OF POTENTIAL INTEREST

- **LUNgevity “No One Missed” Campaign:** Includes patient resources, panel discussions with experts, including with our own faculty, Dr. Raymond Osarogiagbo. [Link](#)
- **The Biomarker Testing Implementation Roadmap for Advanced NSCLC by Association of Community Cancer Centers (ACCC)**, an innovative learning tool to help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, sustain biomarker testing [Link](#)
- **90-Minute 1.5 CME/MOC/CC/NCPD Opportunity from PeerView**-Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment [Link](#)